NCT06966934 Nasopharyngeal Airway Combined With Nasal High-flow Oxygen Therapy During Painless Gastroscopy in Obesity Patients
| NCT ID | NCT06966934 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nanjing First Hospital, Nanjing Medical University |
| Condition | Hypoxia |
| Study Type | INTERVENTIONAL |
| Enrollment | 364 participants |
| Start Date | 2025-05-14 |
| Primary Completion | 2026-05-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 364 participants in total. It began in 2025-05-14 with a primary completion date of 2026-05-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Gastroscopy is a commonly used, direct, and reliable method for screening and diagnosing digestive tract diseases. However, as an invasive examination, it can cause adverse reactions such as pain, nausea, vomiting, and choking cough in patients. Compared with ordinary gastroscopy, painless gastroscopy offers higher comfort and satisfaction for patients and greater convenience for endoscopists during operation. The most common complication of painless gastroscopy diagnosis and treatment is hypoxia. High-flow nasal cannulala (HFNC) provides a higher oxygen concentration and flow rate than an ordinary nasal catheter. It has the functions of heating and humidifying, which can relieve the pressure on the nasal mucosa cilia, keep the airway unobstructed and moist, and reduce the risk of epistaxis. Due to changes in airway anatomical structures such as fat accumulation in the head and neck and hyperplasia of oropharyngeal soft tissues, obese patients are more prone to hypoxia during gastroscopy under sedation. Therefore, HFNC is often used to reduce the occurrence of hypoxia. The nasopharyngeal airway (NPA) is used to maintain the patency of the upper respiratory tract and is suitable for patients with spontaneous breathing but partial obstruction of the upper respiratory tract. It is worth exploring how effective the combination of HFNC and NPA is in improving hypoxemia in obese patients during sedation.
Eligibility Criteria
Inclusion Criteria: 1. Patients undergoing painless gastroscopy; 2. Patients with an age greater than 18 years old; 3. American Society of Anesthesiologists (ASA) physical status classification from Grade I to Grade III; 4. Body Mass Index (BMI) greater than 28 kg/m² Exclusion Criteria: 1. Patients with contraindications to endoscopic procedures or those who refuse sedation/anesthesia; 2. Patients allergic to propofol, eggs, soybeans, milk, etc.; 3. Patients with gastrointestinal tract obstruction and gastric emptying disorders; 4. Patients with acute pharyngitis, tonsillitis, and upper respiratory tract infections; 5. Patients in the acute exacerbation stage of respiratory diseases such as asthma, bronchitis, and chronic obstructive pulmonary disease (COPD); 6. Patients with acute arrhythmia and those with severe heart diseases (congenital diseases, valvular diseases); 7. Patients with severe hepatic and renal insufficiency who require alternative treatment; 8. Patients with severe mental disorders who need medications to control their symptoms; 9. Patients with moderate or above anemia, abnormal coagulation function, and hematological diseases; 10. Patients with nasal cavity lesions leading to severe nasal congestion; 11. Pregnant and lactating patients.
Contact & Investigator
Lihai Chen, Doctor
STUDY DIRECTOR
The First Affiliated Hospital with Nanjing Medical University
Frequently Asked Questions
Who can join the NCT06966934 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hypoxia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06966934 currently recruiting?
Yes, NCT06966934 is actively recruiting participants. Contact the research team at hujingmz@163.com for enrollment information.
Where is the NCT06966934 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT06966934 clinical trial?
NCT06966934 is sponsored by Nanjing First Hospital, Nanjing Medical University. The principal investigator is Lihai Chen, Doctor at The First Affiliated Hospital with Nanjing Medical University. The trial plans to enroll 364 participants.